Status:
UNKNOWN
Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Colon Cancer
Eligibility:
All Genders
14+ years
Brief Summary
The goal of this research study is to identify biologic and lifestyle factors that may increase a person's risk of developing a recurrence (return) of colon cancer.
Detailed Description
Treatment with drugs (chemotherapy) and frequent evaluations by a doctor are standard practice to help prevent colon cancer from recurring after surgery. Despite these measures, the cancer does recur ...
Eligibility Criteria
Inclusion
- Histologically proven adenocarcinoma of the colon. Those patients that do not have tissue available at MDACC for analysis will be eligible to participate in the blood, questionnaire and data portion of the study. They will not participate in the tissue portion of this study.
- AJCC stage II \[T3-4(subscript)N0(subscript)M0(subscript)\]or stage III \[TX(subscript)N1-3(subscript)M0(subscript)\].
- Age \>= 14 yrs old.
- If the patient elects to receive chemotherapy and it is to be administered outside of M. D. Anderson Cancer Center (MDACC), the patient must agree to complete all subsequent surveillance at M.D. Anderson Cancer Center if participating in this clinical trial.
- Ability to understand and the willingness to sign the written informed consent/authorization document.
Exclusion
- Patients who have initiated adjuvant chemotherapy prior to participating in this study will not be included.
- Patients with known history of familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), and any other hereditary polyposis syndrome (Muir Torre, Gardner's Syndrome, etc) will be excluded since these patients are at increased risk for second primary malignancies and are at higher risk of recurrent disease.
- No prior malignancies (excluding non-melanomatous skin neoplasms) over the past 5 years.
- Patients with a known diagnosis of HIV/AIDS or Hepatitis C will be excluded from this study due to their increased risk of second primary malignancies that may complicate appropriate analysis of DFS.
- Patients who are unable to self-administer the protocol questionnaire will be excluded from this study.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00354705
Start Date
January 1 2006
End Date
January 1 2020
Last Update
May 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030